Search

Displaying results 6411 - 6420 of 9705 in total
  1. Drug

    GTI 2040

    go.drugbank.com/drugs/DB05801
    Investigational

    GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.

  2. Drug

    GnRH pharmaccine

    go.drugbank.com/drugs/DB05815
    Experimental

    The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle".

  3. Drug

    Laromustine

    go.drugbank.com/drugs/DB05817
    Investigational

    VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.

  4. Drug

    DP-b99

    go.drugbank.com/drugs/DB05820
    Investigational

    DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment

  5. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure

  6. Drug

    OC-1012

    go.drugbank.com/drugs/DB05834
    Experimental

    OC-1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of mucositis, a serious side effect of chemotherapy and head and neck radiation therapy.

  7. Drug

    NS-3728

    go.drugbank.com/drugs/DB05835
    Experimental

    NS3728 is an orally active chloride channel blocker for the treatment of cancer.

  8. Drug

    OPC-51803

    go.drugbank.com/drugs/DB05838
    Experimental

    It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states.

  9. Drug

    Mito-4509

    go.drugbank.com/drugs/DB05846
    Experimental

    Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways.

  10. Drug

    Rivanicline

    go.drugbank.com/drugs/DB05855
    Experimental

    It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis. … Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype.